PHT Corporation Patient Connect™ Suite Provides Mobile Engagement Apps for Increased Patient Retention and Compliance in Clinical Trials
BOSTON, Mass. and GENEVA, Switzerland – PHT Corporation is expanding its suite of patient-centric apps for improved clinical research. PHT announced the availability of Patient Connect™ Engagement Suite of apps, an integrated set of patient tools now available as part of the PHT electronic clinical outcome assessment (eCOA) System. Pharmaceutical companies and CROs have leveraged the PHT eCOA System in 750+ trials resulting in over 21 regulatory approvals.
Watch a brief demo of the Patient Connect Engagement Suite: http://bit.ly/PHTPatientConnect
75% of 400 leading pharmas and CROs surveyed by eyeforpharma.com cited the “patient” as an organizational priority in 2015. The cost to recruit and enroll patients and dropout rates continue to rise. The Patient Connect Suite helps increase protocol compliance and prevent patient dropouts by improving the patients experience in clinical research. Participation in a study is easier, more engaging and more convenient with this educational and supportive app that can include SMS messaging and access to the patient’s own study data via the StudyWorks™ Patient Portal. Valuable features and communications tools include:
- Trial-specific FAQs, visit guides, instruction manuals and training
- Secure Patient Portal to review data provided and progress dashboard
- Survey tool for collecting feedback, etc.
Sheila Rocchio MBA, PHT Vice President of Marketing and Corporate Strategy, explained, “The development of the Engagement Suite exemplifies the continued innovation at PHT to improve the patient experience during a clinical trial. PHT is adding more services and capabilities trial sponsors are requesting to make it easier and more convenient for patients to participate in studies.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
